What is Elidah?
Founded in 2014 and headquartered in Monroe, Connecticut, Elidah, Inc. operates at the intersection of medical technology and consumer wellness. The company specializes in the development of FDA-cleared, non-invasive devices designed to treat urinary incontinence through neuromuscular stimulation. Its core product, ELITONE, represents a paradigm shift in pelvic floor therapy, allowing users to strengthen muscles discreetly without the need for internal probes, surgery, or pharmaceutical intervention. By leveraging a direct-to-consumer e-commerce model alongside traditional healthcare professional networks, Elidah has established a robust market position. The firm's commitment to innovation is evidenced by its CES Innovation Award recognition and a clear roadmap for future expansion into pelvic pain management and male incontinence indications, signaling a broader ambition to dominate the non-invasive urological health market.
How much funding has Elidah raised?
Elidah has raised a total of $2.8M across 2 funding rounds:
Grant
$750K
Stock/Share Issuance
$2M
Grant (2016): $750K with participation from National Science Foundation
Stock/Share Issuance (2026): $2M, investors not publicly disclosed
Key Investors in Elidah
National Science Foundation
An independent federal agency dedicated to promoting the progress of science and advancing national health through strategic research grants.
Undisclosed Investor
A private capital partner participating in the recent strategic financing round to support company scaling.
Undisclosed Investor
An institutional backer providing growth capital to accelerate the commercialization of medical device technologies.
What's next for Elidah?
With this major enterprise-level funding, Elidah is poised to execute an aggressive growth strategy focused on market penetration and product diversification. The company is expected to scale its manufacturing and distribution capabilities to meet the rising demand for ELITONE, while simultaneously investing in clinical research to support its upcoming product pipeline. Strategic priorities likely include expanding the brand's presence in home medical equipment networks and deepening its integration with healthcare providers. As Elidah matures, the focus will shift toward capturing a larger share of the global pelvic health market, leveraging its unique intellectual property to address underserved patient populations. The company's ability to maintain its technological edge while scaling will be the primary determinant of its long-term success in the competitive medical device landscape.
See full Elidah company page
